Source 1primary paper2025MED
Toolkit/CAR-Tregs
CAR-Tregs
Also known as: chimeric antigen receptor Tregs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
CAR-Tregs are presented as an emerging CAR-based cell therapy approach for autoimmune diseases. In the abstract's framing, CAR-based strategies can help restore immune homeostasis.
Usefulness & Problems
Why this is useful
CAR-Tregs are regulatory T cells engineered with CARs to promote immune tolerance. The abstract specifically states that CAR-Tregs enhance transplant tolerance.; enhancing transplant tolerance; CAR-Tregs are described as chimeric antigen receptor regulatory T cells being studied in transplantation. They are presented as an engineered Treg approach intended to support graft tolerance with less systemic immunosuppression.; engineered antigen-specific Treg therapy; reducing conventional systemic immunosuppression; preventing graft rejection; CAR-Tregs are presented as an emerging CAR-based cell therapy approach for autoimmune diseases. In the abstract's framing, CAR-based strategies can help restore immune homeostasis.; autoimmune disease treatment; restoring immune homeostasis
Source:
CAR-Tregs are regulatory T cells engineered with CARs to promote immune tolerance. The abstract specifically states that CAR-Tregs enhance transplant tolerance.
Source:
enhancing transplant tolerance
Source:
CAR-Tregs are described as chimeric antigen receptor regulatory T cells being studied in transplantation. They are presented as an engineered Treg approach intended to support graft tolerance with less systemic immunosuppression.
Source:
engineered antigen-specific Treg therapy
Source:
reducing conventional systemic immunosuppression
Source:
preventing graft rejection
Source:
CAR-Tregs are presented as an emerging CAR-based cell therapy approach for autoimmune diseases. In the abstract's framing, CAR-based strategies can help restore immune homeostasis.
Source:
autoimmune disease treatment
Source:
restoring immune homeostasis
Problem solved
They address the need for targeted immune regulation in transplantation.; supports immune tolerance in organ transplantation; The approach aims to improve immune regulation in transplantation while reducing dependence on conventional immunosuppression.; need for engineered antigen-directed immune tolerance strategies; They are discussed as a targeted alternative to broad immunosuppression in autoimmune disease.; enabling targeted immune modulation in autoimmune disease
Source:
They address the need for targeted immune regulation in transplantation.
Source:
supports immune tolerance in organ transplantation
Source:
The approach aims to improve immune regulation in transplantation while reducing dependence on conventional immunosuppression.
Source:
need for engineered antigen-directed immune tolerance strategies
Source:
They are discussed as a targeted alternative to broad immunosuppression in autoimmune disease.
Source:
enabling targeted immune modulation in autoimmune disease
Problem links
enabling targeted immune modulation in autoimmune disease
LiteratureThey are discussed as a targeted alternative to broad immunosuppression in autoimmune disease.
Source:
They are discussed as a targeted alternative to broad immunosuppression in autoimmune disease.
need for engineered antigen-directed immune tolerance strategies
LiteratureThe approach aims to improve immune regulation in transplantation while reducing dependence on conventional immunosuppression.
Source:
The approach aims to improve immune regulation in transplantation while reducing dependence on conventional immunosuppression.
supports immune tolerance in organ transplantation
LiteratureThey address the need for targeted immune regulation in transplantation.
Source:
They address the need for targeted immune regulation in transplantation.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
chimeric antigen receptor-mediated antigen recognitionregulatory t cell-mediated immune suppression/tolerance inductionTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The abstract does not specify manufacturing details for CAR-Tregs, but the format implies engineered cellular therapy rather than unmodified cell transfer.; antigen selection is critical; co-stimulatory domain design is important; safety control mechanisms are important
The abstract does not establish mature clinical use in transplantation and notes unresolved issues in dosing, manufacture, antigen specificity, and long-term safety.; further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain; The abstract does not establish disease-specific efficacy and notes broader translational barriers such as specificity, persistence, and manufacturing feasibility.; clinical translation is challenged by antigen specificity; clinical translation is challenged by long-term persistence; clinical translation is challenged by manufacturing feasibility
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2026MED
Source 3primary paper2025MED
Ranked Claims
CAR-NK approaches are being used to target HIV.
CAR-NK approaches targeting HIV
CAR-Tregs enhance transplant tolerance.
CAR-Tregs enhancing transplant tolerance
CD19/BCMA-targeted CAR-T cells have achieved long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression.
CD19/BCMA-targeted CAR-T cells achieving long-term remission in lupus and rheumatoid arthritis without ongoing immunosuppression
Senolytic CARs reduce tissue fibrosis.
senolytic CARs reducing tissue fibrosis
Logic-gated CARs are highlighted as an innovation in next-generation CAR therapy design.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
Off-the-shelf allogeneic CAR products are highlighted as an innovation in CAR-engineered therapies.
Innovations like off-the-shelf allogeneic products and logic-gated CARS are highlighted
The CAR-engineered therapy landscape includes CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
including CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells
Virus-specific T cell therapies targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation
Ex vivo-expanded Tregs in kidney and liver transplantation were associated with reduced rejection rates and lower infection risks.
supporting reduced rejection rates and lower infection risks
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Third-party off-the-shelf and multivirus-specific T cells allow faster availability and standardized scalable manufacturing compared to conventional virus-specific T cells.
Advances in third-party, "off-the-shelf" and multi-VSTs allow faster availability and standardized, scalable manufacturing compared to conventional VSTs.
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
Treg-based therapies including polyclonal Tregs, donor antigen-reactive Tregs, and CAR-Tregs are being studied to minimize conventional systemic immunosuppression while preventing graft rejection.
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Approval Evidence
3 sources4 linked approval claimsfirst-pass slug car-tregs
CAR-Tregs enhancing transplant tolerance
Source:
emerging approaches including CAR-Tregs
Source:
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Source:
clinical applicationsupports
CAR-Tregs enhance transplant tolerance.
CAR-Tregs enhancing transplant tolerance
Source:
field limitationsupports
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Source:
modality scopesupports
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
Source:
therapeutic rationalesupports
Treg-based therapies including polyclonal Tregs, donor antigen-reactive Tregs, and CAR-Tregs are being studied to minimize conventional systemic immunosuppression while preventing graft rejection.
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Source:
Comparisons
Source-stated alternatives
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Source-backed strengths
presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases
Source:
presented as an expanding non-cancer application
Source:
engineered antigen-specific Treg format
Source:
clinical applicability of CAR-T cell therapies extends to autoimmune diseases
Compared with CAAR-T cells
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-engineered macrophages
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-macrophages
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-MΦ
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-NK
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-NK cells
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-NKT cells
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Compared with CAR-T
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-T cells
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-T cell therapy
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with CAR-T therapy
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with chimeric antigen receptor macrophage
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with chimeric antigen receptor macrophages
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with chimeric antigen receptor natural killer cells
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with chimeric antigen receptor T cells
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with Chimeric antigen receptor T-cell therapy
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with donor antigen-reactive Tregs
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Compared with HER2-targeting CAR-M
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.; The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The abstract discusses other CAR-engineered cell modalities such as CAR-T, CAR-NK, CAR-macrophages, and CAR-NKT cells.
Source:
The abstract mentions CAR-T cells, CAAR-T cells, CAR-NK cells, and CAR-macrophages as other CAR-based approaches.
Compared with polyclonal Tregs
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Compared with virus-specific T cell therapies
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Shared frame: source-stated alternative in extracted literature
Strengths here: presented as an expanding non-cancer application; engineered antigen-specific Treg format; clinical applicability of CAR-T cell therapies extends to autoimmune diseases.
Relative tradeoffs: further research is needed to improve antigen specificity; further research is needed to optimize dosing and manufacture; long-term safety concerns remain.
Source:
The source mentions polyclonal Tregs and donor antigen-reactive Tregs as alternative Treg therapy formats, and VSTs for infection-focused indications.
Ranked Citations
- 1.
- 2.
- 3.